Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Total Debt (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Total Debt for 7 consecutive years, with $1.3 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Debt fell 3.61% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Aug 2024, down 3.61%, and an annual FY2024 reading of $1.3 million, down 3.61% over the prior year.
  • Total Debt was $1.3 million for Q3 2024 at CNBX Pharmaceuticals, down from $1.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $1.8 million in Q4 2022 and bottomed at $767420.0 in Q1 2021.
  • Average Total Debt over 4 years is $1.3 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Total Debt soared 101.71% in 2022, then dropped 23.6% in 2023.
  • Year by year, Total Debt stood at $1.1 million in 2021, then surged by 65.0% to $1.8 million in 2022, then fell by 23.8% to $1.3 million in 2023, then dropped by 3.61% to $1.3 million in 2024.
  • Business Quant data shows Total Debt for CNBX at $1.3 million in Q3 2024, $1.3 million in Q3 2023, and $1.3 million in Q2 2023.